These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 37835383)

  • 41. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sex hormone receptors in breast cancer.
    D'Abreo N; Hindenburg AA
    Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
    Pietras RJ; Márquez DC; Chen HW; Tsai E; Weinberg O; Fishbein M
    Steroids; 2005; 70(5-7):372-81. PubMed ID: 15862820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A role for the androgen receptor in the treatment of male breast cancer.
    Zhu J; Davis CT; Silberman S; Spector N; Zhang T
    Crit Rev Oncol Hematol; 2016 Feb; 98():358-63. PubMed ID: 26669267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
    Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TRIM3 facilitates estrogen signaling and modulates breast cancer cell progression.
    Zhuang T; Wang B; Tan X; Wu L; Li X; Li Z; Cai Y; Fan R; Yang X; Zhang C; Xia Y; Niu Z; Liu B; Cao Q; Ding Y; Zhou Z; Huang Q; Yang H
    Cell Commun Signal; 2022 Apr; 20(1):45. PubMed ID: 35392925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
    Osborne CK
    Endocr Relat Cancer; 1999 Jun; 6(2):271-6. PubMed ID: 10731120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
    Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
    Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
    Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
    Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
    Caciolla J; Martini S; Spinello A; Pavlin M; Turrini E; Simonelli F; Belluti F; Rampa A; Bisi A; Fimognari C; Zaffaroni N; Gobbi S; Magistrato A
    Eur J Med Chem; 2021 Nov; 224():113733. PubMed ID: 34364162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.
    Patki M; Salazar Md; Trumbly R; Ratnam M
    Biochem Biophys Res Commun; 2015 Feb; 457(3):404-11. PubMed ID: 25582774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.
    McDermott MS; Chumanevich AA; Lim CU; Liang J; Chen M; Altilia S; Oliver D; Rae JM; Shtutman M; Kiaris H; Győrffy B; Roninson IB; Broude EV
    Oncotarget; 2017 Feb; 8(8):12558-12575. PubMed ID: 28147342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of estrogen receptor-positive breast cancer.
    Lumachi F; Brunello A; Maruzzo M; Basso U; Basso SM
    Curr Med Chem; 2013; 20(5):596-604. PubMed ID: 23278394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
    Johnston SR; Martin LA; Head J; Smith I; Dowsett M
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):173-81. PubMed ID: 15996863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future.
    Yao J; Tao Y; Hu Z; Li J; Xue Z; Zhang Y; Lei Y
    Front Pharmacol; 2023; 14():1225951. PubMed ID: 37808197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.